摘要
非小细胞肺癌(non-small-cell lung cancer,NSCLC)是发病率和死亡率很高的恶性肿瘤之一。随着肿瘤精准治疗快速发展,针对NSCLC的治疗手段也层出不穷。老年患者在NSCLC患者中所占比例最高,如何针对老年患者群体制定合理治疗方案非常重要。本文结合NSCLC治疗传统手段与最新进展,从驱动基因阳性和驱动基因阴性两个方面展开讨论,总结老年晚期NSCLC一线治疗的基本策略,以期为临床治疗提供参考。
Non-small-cell lung cancer(NSCLC)is one of the malignant tumors with high morbidity and mortality.With the rapid devel-opment of precision tumor therapy,new treatments for NSCLC are emerging one after another.Elderly patients account for the highest pro-portion of NSCLC patients,and making rational treatment for the elderly patients is of great importance.This article will combine traditional treatments for NSCLC and the latest progress,and summarize the basic strategies of first-line therapy for elderly patients with advanced driver gene positive and negative NSCLC respectively,so as to provide reference for clinical treatment.
作者
朱潇宽
虞永峰
陆舜
Zhu Xiaokuan;Yu Yongfeng;Lu Shun(Shanghai Lung Tumor Clinical Medical Center,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China)
出处
《实用肿瘤杂志》
CAS
2022年第3期221-226,共6页
Journal of Practical Oncology
关键词
非小细胞肺癌
老年患者
靶向治疗
免疫治疗
non-small-cell lung cancer
elderly patients
targeted therapy
immunotherapy
